文献速递心力衰竭与心肌病

稳定轻症心衰无液体潴留患者短期停用利尿剂的双盲随机试验

Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
PubMed 文献 · Eur Heart J · 2019-01-01

该研究在巴西11家心衰门诊前瞻性纳入188例稳定心衰患者(左室射血分数32±8%),随机分为停用呋塞米组(n=95)与维持组(n=93),双盲评估发现停用低剂量呋塞米未增加呼吸困难自评分(AUC中位数1875 vs 1541,P=0.94),也未显著增加呋塞米再使用需求(75.3% vs 83.7%免于再使用,OR 1.69,95%CI 0.82-3.49,P=0.16),心衰相关事件两组均少见且相似(P=1.0)。

要点

  • 稳定心衰无液体潴留且已用最佳治疗者,停用低剂量呋塞米未加重呼吸困难自评分。
  • 停用利尿剂后呋塞米再使用需求未显著增加(OR 1.69,95%CI 0.82-3.49,P=0.16)。
  • 心衰相关住院、急诊就诊和死亡两组均少见且相似(P=1.0)。

核心结论

  • 在稳定、无液体潴留且接受最佳药物治疗的轻症心衰门诊患者中,停用低剂量呋塞米未增加呼吸困难自感知,也未增加呋塞米再使用需求。
  • 停用利尿剂或可在此类患者中予以考虑。

研究设计与样本

  • 前瞻性、随机、双盲、多中心试验,在巴西11家心衰门诊开展。
  • 共纳入188例稳定心衰门诊患者(25%女性;59±13岁;左室射血分数32±8%),随机分为呋塞米停用组(n=95)与维持组(n=93)。
  • 设两个盲法判定的共同主要终点:呼吸困难视觉模拟评分在基线、第15天、第45天和第90天四个时间点的曲线下面积(AUC),以及随访期间未再使用利尿剂的患者比例。

主要发现

  • 呼吸困难评分AUC中位数在停用组为1875(IQR 383-3360),维持组为1541(IQR 474-3124),组间差异无统计学意义(P=0.94)。
  • 停用组70例(75.3%)、维持组77例(83.7%)在随访期间未再使用呋塞米,停用组额外使用呋塞米的OR为1.69(95%CI 0.82-3.49;P=0.16)。
  • 心衰相关事件(住院、急诊就诊和死亡)少见且两组相似(P=1.0)。

临床怎么用

  • 对稳定、无液体潴留且已接受最佳药物治疗的轻症心衰门诊患者,可考虑停用低剂量呋塞米。
  • 停用利尿剂期间需关注呼吸困难症状及是否需要重新启用利尿剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Although loop diuretics are widely used to treat heart failure (HF), there is scarce contemporary data to guide diuretic adjustments in the outpatient setting. METHODS AND RESULTS: In a prospective, randomized and double-blind protocol, we tested the safety and tolerability of withdrawing low-dose furosemide in stable HF outpatients at 11 HF clinics in Brazil. The trial had two blindly adjudicated co-primary outcomes: (i) symptoms assessment quantified as the area under the curve (AUC) of a dyspnoea score on a visual-analogue scale evaluated at 4 time-points (baseline, Day 15, Day 45, and Day 90) and (ii) the proportion of patients maintained without diuretic reuse during follow-up. We enrolled 188 patients (25% females; 59 ± 13 years old; left ventricular ejection fraction = 32 ± 8%) that were randomized to furosemide withdrawal (n = 95) or maintenance (n = 93). For the first co-primary endpoint, no significant difference in patients' assessment of dyspnoea was observed in the comparison of furosemide withdrawal with continuous administration [median AUC 1875 (interquartile range, IQR 383-3360) and 1541 (IQR 474-3124), respectively; P = 0.94]. For the second co-primary endpoint, 70 patients (75.3%) in the withdrawal group and 77 patients (83.7%) in the maintenance group were free of furosemide reuse during follow-up (odds ratio for additional furosemide use with withdrawal 1.69, 95% confidence interval 0.82-3.49; P = 0.16). Heart failure-related events (hospitalizations, emergency room visits, and deaths) were infrequent and similar between groups (P = 1.0). CONCLUSIONS: Diuretic withdrawal did not result in neither increased self-perception of dyspnoea nor increased need of furosemide reuse. Diuretic discontinuation may deserve consideration in stable outpatients with no signs of fluid retention receiving optimal medical therapy. CLINICALTRIALS.GOV IDENTIFIER: NCT02689180.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Rohde LE, Rover MM, Figueiredo Neto JA, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. Eur Heart J. 2019. PMID: 31424503. doi:10.1093/eurheartj/ehz554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。